Compare SFHG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | INTS |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 19.2M |
| IPO Year | N/A | 2021 |
| Metric | SFHG | INTS |
|---|---|---|
| Price | $2.44 | $5.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 14.8K | ★ 19.4K |
| Earning Date | 10-30-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.19 |
| 52 Week High | $3.17 | $8.06 |
| Indicator | SFHG | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 45.28 |
| Support Level | $0.58 | $5.08 |
| Resistance Level | $2.67 | $8.06 |
| Average True Range (ATR) | 0.23 | 0.34 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 78.87 | 25.73 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.